May 2005
Volume 46, Issue 13
ARVO Annual Meeting Abstract  |   May 2005
Early Corneal and Lacrimal Gland Expression of Inflammatory Genes in a Murine model of Sjogren's Syndrome
Author Affiliations & Notes
  • P.L. Christopherson
    Ophthalmology, Wayne State Univ/Kresge Eye Inst, Detroit, MI
  • J. Smith
    National Eye Institute, Bethesda, MD
  • G. Sosne
    Ophthalmology, Wayne State Univ/Kresge Eye Inst, Detroit, MI
  • Footnotes
    Commercial Relationships  P.L. Christopherson, None; J. Smith, None; G. Sosne, None.
  • Footnotes
    Support  NIH Grant EY15671, Research to Prevent Blindness
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 4462. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      P.L. Christopherson, J. Smith, G. Sosne; Early Corneal and Lacrimal Gland Expression of Inflammatory Genes in a Murine model of Sjogren's Syndrome . Invest. Ophthalmol. Vis. Sci. 2005;46(13):4462.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: The purpose of this study was to investigate early inflammatory gene expression differences in corneas and lacrimal glands from normal [C57BL/6J (BL/6)] and Sjogren’s Syndrome–like B6.MRL Tnfrsf6lpr (MRL/lpr) mice. Methods:8 week old BL/6 and MRL/lpr (n=8/group) mice were sacrificed and the eyes and lacrimal glands were grossly examined and analyzed histologically (H & E staining). Corneas and lacrimal glands were also prepared for RNA and protein analyses. Results: Gross examination and histological analysis showed no apparent inflammatory differences between the groups. However, RT–PCR analysis revealed significant induction of several inflammatory gene mRNA levels in the corneas and lacrimal glands from the MRL/lpr mice compared to BL/6. MRL/lpr corneas had a 1.5 to 8 fold increase over BL/6 for Caspases 1, 3 and 9, for interleukin (IL)–1ß, KC, macrophage inflammatory protein (MIP) –2, matrix metalloproteinase (MMP)–9, plasminogen activator inhibitor (PAI) –1, transforming growth factor (TGF)–ß1, tumor necrosis factor (TNF)–α, and Toll–like receptors (TLR) –4 and –5. Lacrimal gland changes were not as dramatic but showed MRL/lpr increased expression levels over BL/6 for Caspase 1, IL1ß, IL–18, KC, MMP–9, TGFß1 and TLR–4. Conclusions: The MRL/lpr mouse model for inflammatory dry eye disease is useful in determining molecular changes in early corneal and lacrimal gland inflammation in the absence of histolopathological correlation. These novel results suggest that anti–inflammatory therapies initiated before tissue destruction occurs may ameliorate the deleterious dry eye and ocular surface manifestations of Sjogren’s Syndrome.

Keywords: cornea: tears/tear film/dry eye • cytokines/chemokines • inflammation 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.